Category: Treatments & Protocols

When the burning, numbness or electric pain sits in both feet, the question almost everyone asks first is what can be done about it. The honest answer has two halves. There are treatments aimed at the sensation, and there are treatments aimed at whatever is damaging the nerve. Both have a place. Only the second one changes where you end up in five years.

Most feet-first neuropathy is metabolic in origin, and metabolic damage is the kind that responds to being addressed rather than merely muffled. That is the organizing idea behind everything below.

Why the feet go first

The nerves running to your toes are the longest cells in the body. A single sensory axon travels from the base of the spine to the sole of the foot on one continuous supply line, and it is fed by the smallest blood vessels in the peripheral nervous system, the vasa nervorum. That combination — the greatest distance, the highest metabolic demand, the most fragile blood supply — makes the far end of the nerve the first thing to fail when fuel and oxygen delivery falters.

This is why the pattern is so consistent. Symptoms begin in the toes, work upward symmetrically, and reach the fingers only later, when the damage has climbed to about knee height. Clinicians call it a length-dependent or “stocking-glove” distribution, and it is the fingerprint of a systemic process rather than a local injury.¹ We break that pattern down in peripheral neuropathy of the feet symptoms.

This is not only a diabetes problem

In a national sample of 7,116 U.S. adults aged 40 and older, peripheral neuropathy was present in 13.5% of the population — 27.0% of adults with diabetes, but also 11.6% of adults without it. Over a median 13 years of follow-up, neuropathy was independently associated with all-cause mortality in both groups.²

Read that second figure again. More than one in ten adults with no diabetes diagnosis had measurable loss of sensation in the foot. Losing feeling in your feet is not a benign nuisance of aging. It is a signal about the state of the vascular and metabolic system that supplies them.

The metabolic terrain, not just the glucose number

Here is the finding that should change how neuropathy is worked up. When 107 consecutive patients with so-called idiopathic neuropathy were tested properly, 36 of them — 34% — had impaired glucose tolerance, nearly three times the rate in age-matched controls. In many of those patients the fasting glucose and the HbA1c were normal; only the two-hour oral glucose tolerance test was abnormal.³

A normal A1c does not rule out a glucose-driven neuropathy. It rules out one way of measuring glucose handling.

And glucose is only one lever. In 219 patients with idiopathic neuropathy, those with entirely normal blood sugar carried just as heavy a burden of metabolic syndrome features as those with impaired glucose tolerance, with lipid abnormalities particularly prevalent — higher total and LDL cholesterol and more abnormal HDL and triglycerides than a comparison group of people who had diabetes but no neuropathy.⁴

Nerves are damaged by the whole metabolic environment: glucose, insulin resistance, triglycerides, blood pressure, oxidative stress and the microvascular supply, acting together. That is what we mean by nerve terrain, and it is the reason a treatment plan that only adjusts one number tends to stall.

The fibers that fail first in this process are the small ones, which is also why a standard nerve conduction study can read normal while the feet burn every night. That situation is common enough to deserve its own article: small fiber peripheral neuropathy symptoms and testing.

It is also consistent with what we see in our own patients. Fewer than 3% of the people who come to the Padda Institute practice are metabolically healthy by standard criteria, and fewer than 1% of those with chronic pain. Those are practice-reported figures from our own population, not trial outcomes, and individual results vary — but they tell you which direction to look first.

Treatments aimed at the symptom

Medication for neuropathic pain is legitimate and often necessary. It should also be described accurately: it changes what you feel, not what is happening to the nerve.

The 2022 American Academy of Neurology guideline pooled the trial evidence for painful diabetic polyneuropathy and found the major oral drug classes clustered tightly together. Gabapentinoids produced a standardized mean difference of 0.44, SNRIs 0.47, sodium channel blockers 0.56, and SNRI/opioid dual-mechanism agents 0.62 — all sitting just above or just below the threshold for a medium effect. Tricyclic antidepressants showed a large effect size, but with low confidence in the estimate.⁵

Two practical conclusions follow. First, no oral agent is dramatically better than the others, so the choice should be driven by your other conditions, your sleep, your mood and the side effects you can tolerate — and if one class fails, trying a different class is a reasonable next step. Second, the same guideline states that clinicians should not use opioids for painful diabetic neuropathy. That is a formal recommendation, not a preference.

High-concentration topical capsaicin is the one symptomatic treatment with a plausible claim to doing more than muffling. The 8% patch works by defunctionalizing overactive nociceptive fibers in the skin, and there is published evidence of subsequent nerve fiber regeneration alongside the pain relief.⁶ We use it at Regenerve, and it is covered in more depth in our article on the high-concentration capsaicin protocol.

Treatments aimed at the cause

Glucose control — necessary, and by itself not sufficient

A Cochrane review of 17 randomized studies found that tightening glucose control clearly prevents clinical neuropathy in type 1 diabetes, with an annualized risk difference of −1.84%. In type 2 diabetes the same intervention reduced the incidence of clinical neuropathy but did not reach formal statistical significance, though it did significantly improve nerve conduction and vibration thresholds. Tight control also significantly raised the risk of severe hypoglycemia.⁷

This is one of the most useful and least-quoted findings in the field. In type 2 diabetes — the population most of our patients belong to — chasing the glucose number alone does not do the job. The lipid, blood pressure, weight and insulin-resistance components of the terrain have to be treated as part of the neuropathy plan, not as separate problems belonging to a different doctor.

Diet and exercise, measured at the nerve

Thirty-two patients with impaired glucose tolerance and neuropathy received individualized diet and exercise counseling for one year, with skin biopsies before and after. Intraepidermal nerve fiber density improved by 1.4 fibers per millimeter at the proximal site, and the improvement correlated with reduced neuropathic pain.⁸

Nerve fibers grew back. Not in an animal model — in people, measured on biopsy, after a year of changing what they ate and how much they moved. This remains one of the strongest arguments for treating the metabolic terrain as the primary intervention rather than the lifestyle advice you give on the way out the door. We cover the training side of this in exercises for peripheral neuropathy in the feet.

Finding the driver that is not metabolic

Not every neuropathy is metabolic, and some of the non-metabolic causes are correctable. The ones worth ruling in or out include functional B12 deficiency, which can be present despite a normal B12 level; gluten-related nerve injury, including cases with a negative celiac test; autoimmune disease; medications including statins and long-term metformin; heavy metals, mold and mycotoxins and alcohol; malabsorption after surgery; and nerve compression, which can coexist with a metabolic neuropathy and make it worse. The full account is in the 11 hidden drivers of peripheral neuropathy.

The therapies we add on top

Once the driver is identified, treatment can be aimed at it. At our St. Louis clinic that toolkit includes class 4 photobiomodulation, class 3B cold laser, whole-body infrared, peripheral and vagal nerve stimulation, nutritional counseling, balance and gait training, and wound care where protective sensation has been lost. Orthobiologic injections including PRP and BMAC are also offered, used as adjuncts inside a plan — never as a substitute for finding the cause. The full list is on our services page, and the reasoning behind the sequence is in the Regenerve Protocol.

Supplements and complementary approaches

Some have real randomized evidence — alpha-lipoic acid, acetyl-L-carnitine, palmitoylethanolamide and acupuncture among them — and some widely sold products have failed when properly tested. We grade them one by one in alternative medicine for peripheral neuropathy.

Protecting the feet while you treat them

When sensation drops below a certain threshold, the foot stops reporting injury. That is what makes neuropathy dangerous rather than merely uncomfortable. A 10-gram monofilament test identifies loss of protective sensation, and anyone who has it needs daily visual foot checks, properly fitted footwear, and prompt attention to any blister, crack or callus — because the usual warning signal is gone.⁹ Never soak numb feet in water you have not tested with your hand or a thermometer.

Honest expectations

Nerve tissue repairs slowly and not all damage is reversible. Progress is measured in reduced pain, better sleep, steadier balance and improved function — usually over months, not weeks. Anyone promising a cure for peripheral neuropathy is telling you something that cannot be supported. What can often be changed is the trajectory, particularly when an active driver is found and treated.

Being evaluated in St. Louis

Regenerve is at 4477 Woodson Rd #104, St. Louis, MO 63134, minutes from St. Louis Lambert International Airport, and is led by Dr. Gurpreet Singh Padda, MD, MBA, MHP. The practice serves the St. Louis region, Missouri and Illinois. Electrodiagnostic testing is performed on site, so the evaluation and the results happen in the same place.

Call or text (314) 886-5902, or email info@regenerve.com. Office hours are Monday through Thursday 9:00 to 16:00 and Friday 9:00 to 13:30. Details are on the contact page and the locations page.

The clearest place to begin is the Nerve Damage Score, a five-question assessment that produces a large-print report you can bring to any physician.

Frequently asked questions

What is the best treatment for peripheral neuropathy in the feet?

There is no single best treatment, because the right one depends on what is damaging the nerve. Pain medication, topical capsaicin, metabolic correction and nerve-directed therapies all have a place, and the plan should follow the diagnosis rather than precede it. See the Regenerve Protocol.

What is the best treatment for diabetic neuropathy in the feet?

There is no single drug that fixes it. In diabetes the nerve damage is driven by the metabolic terrain, so the treatment that changes the nerve is the treatment aimed at that terrain — and nerve fibers can regrow, measured on skin biopsy, though it is work measured in months and no one can promise a cure.

Pain-directed medication is worth having in the meantime, but it helps not to confuse the two: gabapentinoids, SNRIs and tricyclics treat the pain and not the nerve damage, and the major oral classes cluster tightly together in effect.

The reason the plan cannot stop at glucose is the evidence itself. A Cochrane review of 17 randomized studies found that tightening glucose control clearly prevents clinical neuropathy in type 1 diabetes, but in type 2 — the population most of our patients belong to — it reduced incidence without reaching statistical significance, while significantly raising the risk of severe hypoglycemia. Glucose is one lever and not the whole plan: lipids, blood pressure, weight and insulin resistance belong in the neuropathy plan rather than to a different doctor. See diabetic peripheral neuropathy treatment in St. Louis.

Can peripheral neuropathy in the feet be reversed?

Some of it can. Diet and exercise counseling in patients with impaired glucose tolerance produced measurable regrowth of nerve fibers on skin biopsy after one year. Not all damage is reversible, and no one can promise a cure. See how sugar damages nerves.

My A1c is normal. Can my neuropathy still be metabolic?

Yes. In one study of patients with idiopathic neuropathy, 34% had impaired glucose tolerance that a normal fasting glucose and normal HbA1c had missed, and only the two-hour glucose tolerance test revealed it. See how sugar damages nerves.

Should I be taking gabapentin or pregabalin?

They are reasonable options with a modest average effect, comparable to SNRIs, tricyclics and sodium channel blockers. They treat the pain and not the nerve damage, so they work best alongside treatment aimed at the cause. See the hidden drivers of peripheral neuropathy.

Are opioids used for neuropathy in the feet?

The American Academy of Neurology recommends against using opioids for painful diabetic polyneuropathy. Our practice reduces opioid burden rather than adding to it. See which specialist you should see.

How long before treatment helps?

Symptom-directed treatments can work within weeks. Treatment aimed at the underlying metabolic driver is measured in months, because it depends on nerve fibers regrowing. See the Regenerve Protocol.

Sources

1. Tesfaye S, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010. PMID 20876709
2. Hicks CW, Wang D, Matsushita K, Windham BG, Selvin E. Peripheral Neuropathy and All-Cause and Cardiovascular Mortality in U.S. Adults: A Prospective Cohort Study. Annals of Internal Medicine. 2021. PMID 33284680
3. Singleton JR, Smith AG, Bromberg MB. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care. 2001. PMID 11473085
4. Smith AG, Rose K, Singleton JR. Idiopathic neuropathy patients are at high risk for metabolic syndrome. Journal of the Neurological Sciences. 2008. PMID 18606421
5. Price R, et al. Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary. Neurology. 2022. PMID 34965987
6. Anand P, et al. Reversing painful and non-painful diabetic neuropathy with the capsaicin 8% patch: clinical evidence for pain relief and restoration of function via nerve fiber regeneration. Frontiers in Neurology. 2022. PMID 36388188
7. Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database of Systematic Reviews. 2012. PMID 22696371
8. Smith AG, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care. 2006. PMID 16732011
9. Boulton AJM, et al. Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of the American Diabetes Association. Diabetes Care. 2008. PMID 18663232

People look for alternative treatments for peripheral neuropathy for a reasonable reason: the standard drugs treat the pain and not the nerve, and their average effect is modest. That is a real gap, and it is worth filling. It is also the gap that the supplement industry has filled with a great deal of confident marketing and very little published data.

What follows is a grading of the non-drug options by the evidence that actually exists — what has randomized trial support, what has weak support, what has failed when properly tested, and the one intervention that outperforms every bottle on the shelf.

Start with what the label “alternative” is hiding

Most people searching for alternative medicine for neuropathy have already been told there is nothing to be done about the cause. In a large share of cases that is not true — the cause simply was not looked for thoroughly enough.

Among 107 patients whose neuropathy had been called idiopathic, 34% had impaired glucose tolerance, close to three times the rate in matched controls, and in many of them fasting glucose and HbA1c were normal. Only a two-hour oral glucose tolerance test found it.¹ In a separate series of 219 idiopathic neuropathy patients, even those with entirely normal blood sugar carried a heavy burden of metabolic syndrome features, with lipid abnormalities particularly prevalent.²

So before spending money on supplements, it is worth confirming that the workup included an OGTT, a full lipid panel, B12 with methylmalonic acid, thyroid studies, and a review of medications. The 11 hidden drivers of peripheral neuropathy covers the rest of that list, and if your nerve conduction study came back normal while your feet still burn, read small fiber peripheral neuropathy symptoms and testing before concluding that nothing was found.

The strongest non-drug intervention is not a supplement

Diet and exercise directed at the metabolic terrain has better evidence than anything sold as a nerve supplement — and it is measured at the nerve, not on a questionnaire.

Thirty-two patients with impaired glucose tolerance and neuropathy received individualized diet and exercise counseling for one year, with skin biopsies at baseline and at 12 months. Intraepidermal nerve fiber density improved by 1.4 fibers per millimeter at the proximal site, and that improvement correlated with reduced neuropathic pain.³ A separate 10-week supervised aerobic and resistance program in patients with diagnosed diabetic peripheral neuropathy produced significant reductions in pain and neuropathic symptoms alongside increased intraepidermal nerve fiber branching on biopsy.⁴

A 2022 systematic review with meta-analysis of 41 randomized controlled trials concluded that for diabetic peripheral neuropathy the evidence now supports a specific recommendation: a combination of endurance and sensorimotor training, with benefits across balance measures, functional mobility, peroneal and sural nerve conduction velocity, and HbA1c.⁵

Nothing in the supplement aisle has that level of support. The practical program is in exercises for peripheral neuropathy in the feet.

Alpha-lipoic acid: real evidence, with an important qualifier

Alpha-lipoic acid is an antioxidant and the best-studied supplement in this field. A meta-analysis of four randomized, double-blind, placebo-controlled trials — ALADIN I, ALADIN III, SYDNEY and NATHAN II, totaling 1,258 patients — found a 24.1% relative improvement in the Total Symptom Score in the feet versus placebo after three weeks, with responder rates of 52.7% on alpha-lipoic acid against 36.9% on placebo. Pain, burning and numbness all improved, as did pinprick and touch-pressure sensation and ankle reflexes, with no difference in adverse event rates.⁶

The qualifier matters: that evidence is for 600 mg given intravenously, daily for three weeks. The oral capsules sold over the counter are not the same intervention, and their evidence is considerably weaker. If a supplement is recommended to you on the strength of “the ALADIN trials,” it is fair to ask whether the study used the oral form.

Acetyl-L-carnitine: modest, in a specific population

Acetyl-L-carnitine improved pain, vibratory perception and measures of nerve regeneration in patients with chronic diabetic neuropathy in randomized trial data, with the clearest effect in those treated earlier in the disease course.⁷ It is a reasonable adjunct with a real, if modest, evidence base. It is not a substitute for treating the driver.

Palmitoylethanolamide: promising, and worth reading carefully

Palmitoylethanolamide, or PEA, is a naturally occurring fatty acid amide. A systematic review and meta-analysis of 11 double-blind randomized controlled trials covering 774 patients with chronic pain found reduced pain scores relative to comparators, with no major side effects attributed to PEA in any study.⁸ The authors noted that optimal dosing and administration still need to be determined, and the trials pooled were across chronic pain generally rather than neuropathy alone.

PEA is one of the supportive agents we use at our St. Louis clinic, within a plan rather than as a standalone answer.

Acupuncture: low-certainty evidence, genuine effect size

A 2025 systematic review and meta-analysis of 14 randomized trials covering 1,169 participants found that, compared with sham, acupuncture may reduce pain in diabetic peripheral neuropathy by 1.44 cm on a 10 cm visual analog scale, and may reduce overall neurologic symptom severity, with little to no difference in adverse events. The authors graded the certainty of that evidence as low.⁹

Low certainty does not mean it does not work. It means the trials were small or at risk of bias and the estimate could move. Given the safety profile, acupuncture is a defensible thing to try alongside cause-directed treatment.

Topical capsaicin: the one that may do more than mask

High-concentration capsaicin at 8% is a prescription patch rather than a store-bought cream, but people often find it while searching for natural options because capsaicin comes from chili peppers. It works by defunctionalizing overactive nociceptive fibers in the skin, and there is published evidence of subsequent nerve fiber regeneration accompanying the pain relief.¹⁰ We use it, and it is covered in the high-concentration capsaicin protocol.

Light-based therapies: mechanistic rationale, thin trial evidence

Photobiomodulation targets cytochrome c oxidase in mitochondria and is intended to support energy production and circulation in injured nerve tissue. We offer class 4 photobiomodulation, class 3B cold laser and whole-body infrared at the clinic, and describe them on the services page.

The honest statement of the evidence is that the mechanistic rationale is coherent and the randomized trial base for diabetic peripheral neuropathy is still limited — several systematic reviews have been registered and published as protocols rather than completed syntheses. We use these therapies as adjuncts within a plan built on identifying and treating the cause, and we do not present them as the treatment.

What has failed when properly tested

This section matters as much as the others. Benfotiamine, a fat-soluble thiamine derivative sold widely for neuropathy, was tested in a 12-month randomized, placebo-controlled, double-blind trial in type 2 diabetes patients with symptomatic polyneuropathy. It raised blood levels of all six thiamine analytes measured, confirming it was absorbed and doing something biochemically. It produced no significant effect on corneal nerve fiber length, on the secondary morphometric, functional and clinical neuropathy outcomes, or on quality of life.¹¹

That is what a well-conducted negative trial looks like, and it is a useful benchmark. Ask of any product marketed for neuropathy: has it been tested this way, and what happened?

Things worth being skeptical about

• Any product or program promising to cure, reverse or eliminate neuropathy. Nerve recovery is partial, slow and dependent on the cause. A cure claim is a marketing claim.
• Proprietary “nerve support” blends that combine a dozen ingredients at doses below those used in any trial, so no individual component reaches a studied dose.
• Fixed packages of sessions sold before a diagnosis. The number of treatments should follow clinical need and response, not a package purchased in advance.
• High-dose vitamin B6. Excess B6 causes a sensory neuropathy in its own right. More is not better here.
• Anything that requires stopping your prescribed medication to work.

How we think about this

Alternative and complementary approaches are not a separate category of medicine to us. They are treatments with an evidence base to be graded like any other. Where the evidence supports something, we use it; where it does not, we say so; and none of it substitutes for identifying what is damaging the nerve. That sequencing is set out in the Regenerve Protocol, and the full treatment landscape is in peripheral neuropathy treatments for the feet.

Talk to your physician before starting any supplement, particularly if you take anticoagulants, thyroid medication or diabetes medication, and note that alpha-lipoic acid can lower blood glucose.

Being evaluated in St. Louis

Regenerve is at 4477 Woodson Rd #104, St. Louis, MO 63134, minutes from St. Louis Lambert International Airport, and is led by Dr. Gurpreet Singh Padda, MD, MBA, MHP. The practice serves the St. Louis region, Missouri and Illinois. Electrodiagnostic testing is performed on site.

Call or text (314) 886-5902, or email info@regenerve.com. Office hours are Monday through Thursday 9:00 to 16:00 and Friday 9:00 to 13:30. Details are on the contact page and the locations page.

Before buying anything, the Nerve Damage Score is a five-question assessment that produces a large-print report you can bring to any physician.

Frequently asked questions

What is the best alternative treatment for peripheral neuropathy?

Diet and exercise aimed at the metabolic terrain has the strongest evidence, including measured regrowth of nerve fibers on skin biopsy. No supplement matches it. See exercises for peripheral neuropathy in the feet.

Does alpha-lipoic acid work for neuropathy?

The strong trial evidence is for 600 mg given intravenously over three weeks, which produced a 24.1% relative improvement in symptom scores versus placebo. Evidence for over-the-counter oral capsules is considerably weaker. See how sugar damages nerves.

Does acupuncture help neuropathy in the feet?

A meta-analysis of 14 randomized trials found acupuncture may reduce pain and neurologic symptom severity compared with sham, with low certainty of evidence and few adverse events. See peripheral neuropathy treatments for the feet.

Should I take benfotiamine for neuropathy?

A 12-month randomized placebo-controlled trial found benfotiamine raised thiamine levels but had no significant effect on nerve structure, nerve function, clinical neuropathy measures or quality of life. See functional B12 deficiency and neuropathy.

Are supplements enough on their own?

No. Supplements address one input at a time, while neuropathy is driven by the whole metabolic environment plus any nutritional, autoimmune, toxic or structural driver present. See the hidden drivers of peripheral neuropathy.

Can vitamins make neuropathy worse?

Yes. High-dose vitamin B6 can cause a sensory neuropathy of its own, so supplementing without knowing your levels can add a driver rather than remove one. See functional B12 deficiency and neuropathy.

Sources

1. Singleton JR, Smith AG, Bromberg MB. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care. 2001. PMID 11473085
2. Smith AG, Rose K, Singleton JR. Idiopathic neuropathy patients are at high risk for metabolic syndrome. Journal of the Neurological Sciences. 2008. PMID 18606421
3. Smith AG, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care. 2006. PMID 16732011
4. Kluding PM, et al. The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy. Journal of Diabetes and its Complications. 2012. PMID 22717465
5. Streckmann F, et al. Exercise and Neuropathy: Systematic Review with Meta-Analysis. Sports Medicine. 2022. PMID 34964950
6. Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabetic Medicine. 2004. PMID 14984445
7. Sima AAF, et al. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy. Diabetes Care. 2005. PMID 15616239
8. Lang-Illievich K, et al. Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials. Nutrients. 2023. PMID 36986081
9. Lan L, et al. Acupuncture for the Management of Chronic Diabetic Peripheral Neuropathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Current Pain and Headache Reports. 2025. PMID 40220243
10. Anand P, et al. Reversing painful and non-painful diabetic neuropathy with the capsaicin 8% patch: clinical evidence for pain relief and restoration of function via nerve fiber regeneration. Frontiers in Neurology. 2022. PMID 36388188
11. Ziegler D, et al. Effects of benfotiamine treatment over 12 months on morphometric, neurophysiological and clinical measures in type 2 diabetes patients with symptomatic polyneuropathy (BOND study). BMJ Open Diabetes Research & Care. 2026. PMID 41571333

Exercise is the only treatment for peripheral neuropathy in the feet that has been shown, in people rather than animals, to change the nerve fibers themselves — and it is usually mentioned last, on the way out the door.

This article sets out what the trials actually tested, why it works, and a practical weekly program you can start with, including the foot-protection rules that make exercising on numb feet safe.

What the evidence says

A 2022 systematic review with meta-analysis pooled 41 randomized controlled trials of exercise in patients with neuropathy, 27 of them in diabetic peripheral neuropathy. The authors concluded that evidence-based recommendations can now be made for this population, and that the most beneficial approach is a combination of endurance and sensorimotor training. Effects favored exercise across static balance, the Berg Balance Scale, the Timed Up and Go test, peroneal and sural nerve conduction velocity, and HbA1c.¹

Note what is in that list. Not just “patients felt better” — nerve conduction velocity and HbA1c both moved. Exercise is acting on the nerve and on the metabolic environment that damaged it.

Two smaller studies show the same thing at the level of the nerve fiber. A 10-week supervised aerobic and resistance program in 17 people with diagnosed diabetic peripheral neuropathy produced significant reductions in pain and in neuropathic symptoms, together with increased intraepidermal nerve fiber branching on skin biopsy.² And a year of individualized diet and exercise counseling in 32 patients with impaired glucose tolerance and neuropathy improved intraepidermal nerve fiber density by 1.4 fibers per millimeter at the proximal biopsy site, with the improvement correlating with reduced neuropathic pain.³

These were small studies without large control groups, and they are not a promise of recovery. They are, however, direct evidence that nerve fibers respond to a change in the metabolic environment.

Why it works: the metabolic explanation

The nerves to your toes are the longest cells in the body, fed by the smallest blood vessels. They fail first when fuel and oxygen delivery falters. Exercise attacks that problem from several directions at once: it improves insulin sensitivity and glucose handling, lowers triglycerides, raises HDL, improves microvascular function, and increases blood flow to the vasa nervorum that supply the nerve itself.

That breadth is exactly what this condition needs. Tightening glucose control alone has a clear preventive effect in type 1 diabetes but a much weaker one in type 2, where the lipid, blood pressure and insulin-resistance components of the terrain carry substantial weight.⁴ Among patients with idiopathic neuropathy, even those with entirely normal blood sugar carried a heavy burden of metabolic syndrome features, particularly abnormal lipids.⁵ Exercise is one of the few interventions that moves all of those at once. The mechanism is covered further in how sugar damages nerves.

Before you start

• Get cleared. Talk to your physician first, particularly if you have cardiac disease, retinopathy, kidney disease, an open wound, or an unexplained hot, swollen foot — the last of these needs evaluation before any weight-bearing exercise.
• Inspect both feet before and after every session, including between the toes and the soles, using a mirror if you cannot see them easily. When protective sensation is reduced, the foot stops reporting injury, which is why the visual check replaces the pain you would normally feel.⁶
• Wear properly fitted athletic shoes and seamless socks. Check inside the shoe with your hand before putting it on.
• Have support available. Do balance work next to a counter, a wall or a sturdy chair.
• Stop for any new blister, hot spot, unusual swelling, chest symptoms or a fall.

A weekly program

The evidence points to endurance plus sensorimotor training, with resistance work supporting both. Build to this over four to six weeks rather than starting at the top.

1. Endurance — 3 to 5 days per week

Start with 10 minutes and add 2 to 3 minutes per week, working toward 30 minutes at a pace where you can talk but not sing. Walking is the default. If foot pain, ulcer risk or balance make walking unwise, a stationary bike, a recumbent bike, a rowing machine, an arm ergometer or water walking deliver the same metabolic benefit while offloading the foot.

2. Sensorimotor and balance work — 3 to 5 days per week, 10 to 15 minutes

This is the component the meta-analysis identified as most crucial, and it is the one people skip. Always work within reach of a support.

• Feet-together stand — 30 seconds, progressing to eyes closed once it is easy with eyes open
• Semi-tandem then tandem stand — one foot partly, then fully in front of the other, 20 to 30 seconds each side
• Single-leg stand — start at 5 to 10 seconds per side, build toward 30
• Heel-to-toe walking — 10 steps along a countertop
• Weight shifts — forward, back and side to side, slowly, feeling the pressure move across the foot
• Head turns while standing — a harder challenge that trains the vestibular contribution to balance
• Foam or cushion standing — only once firm-ground work is reliably steady

Progress by removing input rather than by adding time: eyes open to eyes closed, two hands on the counter to one finger to none, firm surface to compliant surface.

3. Resistance — 2 to 3 days per week, non-consecutive

Two to three sets of 10 to 15 repetitions of a small number of compound movements: sit-to-stand from a chair, heel raises, seated or standing leg press or wall squat, hamstring curls, hip abduction, and rows or presses for the upper body. Elastic-band resistance training has been studied specifically in older adults with diabetic peripheral neuropathy for its effect on balance and fear of falling, and it requires no equipment beyond a band.⁷

4. Foot and ankle mobility — daily, 5 minutes

• Ankle pumps, circles, and alphabet tracing with the toes
• Toe curls and spreads, and picking up a towel with the toes
• Calf and Achilles stretches — 30 seconds each side, twice
• Seated rolling of the sole over a ball, gently, and never on numb skin you have not inspected

5. Interrupt the sitting

Stand and move for two to three minutes every 30 minutes. This is not filler. Uninterrupted sitting worsens glucose handling independently of whether you exercised earlier that day, and glucose handling is the thing you are trying to change.

What to expect, and when

Balance and steadiness usually improve first, often within four to six weeks, because they depend partly on training the remaining sensory input and the muscles that use it. Pain and burning tend to shift over two to three months. Changes at the level of nerve fibers were measured at 10 weeks in one study and at 12 months in the other — this is a long-horizon intervention.

Some people notice a temporary increase in sensation or discomfort in the first weeks. That usually settles. Sharp new pain, a hot or swollen foot, or any open area means stop and be seen.

Exercise is not the whole plan

Exercise is the highest-yield thing you can do yourself. It does not replace finding out what is damaging the nerve. If the driver is a B12 deficiency, gluten-related injury, a medication, a toxic exposure or nerve compression, that needs to be addressed directly. The full list is in the 11 hidden drivers of peripheral neuropathy, how exercise fits alongside medical treatment is in peripheral neuropathy treatments for the feet, and the supplements people usually ask about next are graded in alternative medicine for peripheral neuropathy.

Being evaluated in St. Louis

Regenerve is at 4477 Woodson Rd #104, St. Louis, MO 63134, minutes from St. Louis Lambert International Airport, and is led by Dr. Gurpreet Singh Padda, MD, MBA, MHP. The practice serves the St. Louis region, Missouri and Illinois. Balance and gait training, physical rehabilitation and nutritional counseling are part of what we offer, and electrodiagnostic testing is performed on site. The full list is on the services page.

Call or text (314) 886-5902, or email info@regenerve.com. Office hours are Monday through Thursday 9:00 to 16:00 and Friday 9:00 to 13:30. Details are on the contact page and the locations page.

If you are not sure how far your neuropathy has progressed, the Nerve Damage Score is a five-question assessment that produces a large-print report you can bring to any physician.

Frequently asked questions

What are the best exercises for peripheral neuropathy in the feet?

A combination of endurance training and sensorimotor or balance training, supported by resistance work. That combination is what a meta-analysis of 41 randomized trials identified as most beneficial in diabetic peripheral neuropathy. See peripheral neuropathy treatments for the feet.

Is walking safe if my feet are numb?

Usually yes, with properly fitted shoes and a visual inspection of both feet before and after every session, because a numb foot no longer reports injury. Any open wound or a hot, swollen foot needs evaluation before weight-bearing exercise. See peripheral neuropathy of the feet symptoms.

Can exercise regrow damaged nerves?

There is evidence that it can contribute. A 10-week supervised exercise program increased intraepidermal nerve fiber branching on skin biopsy, and a year of diet and exercise counseling increased nerve fiber density. Recovery is partial and slow, and no one can promise a cure. See small fiber neuropathy symptoms and testing.

How long until exercise helps my neuropathy?

Balance and steadiness often improve within four to six weeks. Pain and burning typically shift over two to three months, and changes measured at the nerve fiber were seen at 10 weeks and at 12 months in the published studies. See the Regenerve Protocol.

What if I cannot walk far or my balance is poor?

Use a seated or supported alternative for the endurance component — a recumbent bike, an arm ergometer or water walking — and do balance work holding a counter. The metabolic benefit does not require walking. See the hidden drivers of peripheral neuropathy.

Should I exercise if it makes my feet hurt more?

A temporary increase in sensation in the first weeks is common and usually settles. Sharp new pain, a new blister or hot spot, or a hot and swollen foot means stop and be evaluated. See which specialist you should see.

Sources

1. Streckmann F, et al. Exercise and Neuropathy: Systematic Review with Meta-Analysis. Sports Medicine. 2022. PMID 34964950
2. Kluding PM, et al. The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy. Journal of Diabetes and its Complications. 2012. PMID 22717465
3. Smith AG, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care. 2006. PMID 16732011
4. Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database of Systematic Reviews. 2012. PMID 22696371
5. Smith AG, Rose K, Singleton JR. Idiopathic neuropathy patients are at high risk for metabolic syndrome. Journal of the Neurological Sciences. 2008. PMID 18606421
6. Boulton AJM, et al. Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of the American Diabetes Association. Diabetes Care. 2008. PMID 18663232
7. Armat MR, et al. The Effect of Resistance Exercises Using an Elastic Band on Balance and Fear of Falling in Older Adults With Diabetic Peripheral Neuropathy. Archives of Physical Medicine and Rehabilitation. 2024. PMID 38218307

If you live with peripheral neuropathy, you already know the standard script: a prescription for gabapentin or pregabalin, a suggestion to control your blood sugar, and a shrug when neither one gives your feet back to you. The Regenerve protocol starts from a different premise — that burning, tingling, and numbness are not the disease but the alarm, and that the goal of treatment is to repair the terrain the nerves live in, not simply to mute the signal they are sending. This article walks through the logic of that protocol, the science behind each stage, and an honest accounting of what is established and what is less certain.

Why symptom suppression alone falls short

The medications most people are handed — the gabapentinoids (gabapentin, pregabalin) and certain antidepressants (duloxetine, amitriptyline) — work by dampening the transmission of pain signals in the nervous system. They are legitimate tools, and for many patients they take the edge off. But two facts are rarely explained at the pharmacy counter.

First, the benefit is often partial. Across the neuropathic-pain literature, only a minority of patients achieve substantial (50% or greater) pain relief from any single oral agent, and many discontinue because of side effects like sedation, dizziness, weight gain, and cognitive fog. Second — and more fundamentally — none of these drugs touch the process that is damaging the nerve. They quiet the alarm while the fire keeps burning. That is why patients so often describe climbing to the maximum dose and still waking at 3 a.m. with their feet on fire.

The Regenerve premise is that lasting change requires addressing why the nerve is failing, then giving it the conditions to recover.

Metabolic sovereignty: treating the terrain, not just the nerve

Dr. Padda uses the phrase “metabolic sovereignty” to describe the underlying philosophy: your nerves cannot heal in a hostile environment. A nerve fiber is one of the most metabolically demanding structures in the body. It must maintain an electrical gradient along its entire length, transport nutrients and mitochondria from the cell body out to the nerve endings, and constantly repair its insulating myelin. Starve it of oxygen, poison it with the byproducts of high blood sugar, or drain its energy supply, and it will misfire, retract, and eventually die back — starting at the longest, most distant fibers, which is why symptoms begin in the toes and feet.

So before any regenerative step makes sense, the terrain has to be assessed and corrected: blood sugar and glycation, micronutrient status, circulation, inflammatory drivers, and mechanical contributors. This is the diagnostic backbone that a companion article — “The 11 Hidden Drivers Your Doctor Missed” — explores in depth. The protocol below assumes that this root-cause work is happening in parallel; the regenerative tools are not a substitute for it.

Stage one: quiet the overfiring nerve

When a damaged nerve becomes chronically hyperexcitable, it fires pain even in the absence of a real threat. One way to interrupt that is to “defunctionalize” the overactive pain fibers at the skin level using high-concentration capsaicin.

The 8% capsaicin patch (marketed as Qutenza) is the most evidence-backed piece of this stage. It works on the TRPV1 receptor — the same receptor that makes chili peppers feel hot — which sits on the small pain-sensing C-fibers in the skin. A single controlled application overstimulates and then reversibly “switches off” those endings, reducing their pain signaling for weeks to months. This is not folk medicine: the U.S. FDA approved the 8% capsaicin patch for postherpetic neuralgia in 2009 and, after the pivotal STEP trial led by Dr. David Simpson, for painful diabetic peripheral neuropathy of the feet in 2020. In the controlled data, a single 30-minute treatment produced modest but statistically significant reductions in daily pain, with the main side effect being temporary application-site burning, and — importantly — no deterioration in patients’ ability to sense sharp, warm, cold, or vibration stimuli. A separate 52-week safety study (PACE) supported repeated treatment without functional or neurological harm.

An honest caveat belongs here, because it is where marketing often overreaches: the established benefit of capsaicin is pain relief, not proven nerve regrowth. Whether repeated capsaicin treatment can help damaged nerve fibers actually regenerate is a genuine scientific question currently under formal investigation (including a randomized disease-modification trial out of Cambridge), not a settled fact. Regenerve uses capsaicin to create a window of reduced pain and reduced nociceptor overactivity — a window in which the repair-focused steps have room to work.

Stage two: support structural repair with orthobiologics

Once the fire is calmer and the terrain is being corrected, the protocol turns to helping the tissue rebuild. This is where orthobiologics enter — biological materials intended to deliver growth factors and signaling molecules to injured tissue. In the Regenerve protocol these include platelet-rich plasma (PRP) and bone marrow aspirate concentrate (BMAC), both derived from the patient’s own blood or marrow.

The rationale is grounded in real biology. Platelets are packed with growth factors — including nerve growth factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and platelet-derived growth factor — that orchestrate healing, angiogenesis (new blood-vessel formation), and, in laboratory and animal models, peripheral nerve regeneration. BMAC additionally supplies a mesenchymal cell population that can modulate inflammation.

Here transparency is essential, and Regenerve’s material is careful about it: PRP and BMAC for peripheral nerve repair are offered as part of an individualized plan. The strongest evidence to date comes from preclinical models and small clinical series, not large randomized trials, and these therapies are not FDA-approved specifically for peripheral neuropathy. Presented honestly, they are a mechanism-driven, patient-derived intervention with encouraging early signals and an incomplete evidence base — which is exactly why they belong in a physician-directed, individualized plan with realistic expectations, not a one-size-fits-all promise.

Stage three: restore the cellular power plant

Even a structurally intact nerve cannot function if its mitochondria — the energy generators inside each cell — are failing. Chronic hyperglycemia, toxins, and nutrient deficiencies all converge on mitochondrial dysfunction, and Dr. Michael Brownlee’s landmark work showed that overproduction of mitochondrial superoxide is a unifying mechanism behind the tissue damage of diabetes. Repairing the wiring without restoring the power supply leaves the job half done.

The protocol therefore incorporates mitochondrial support. This ranges from well-established repletion of the cofactors nerves depend on — the B vitamins, alpha-lipoic acid, and CoQ10 among them — to more advanced, targeted agents. SS-31 (elamipretide) is a mitochondria-targeted peptide designed to stabilize cardiolipin in the inner mitochondrial membrane and improve energy production; it is a real and actively studied compound, but it remains investigational and is not an FDA-approved neuropathy treatment. As with the orthobiologics, the honest framing is that the mitochondrial-support layer combines proven nutritional science with newer, still-experimental tools, selected case by case.

Why sequence matters

The order is deliberate. Correcting the terrain first means the body is no longer actively re-injuring the nerve. Calming the overfiring pain fibers next creates a period of reduced pain and reduced nociceptor chaos. Delivering repair signals and restoring mitochondrial energy last gives the nerve both the instructions and the fuel to recover during that window. Reverse the order — try to “regenerate” a nerve that is still being starved and glycated every day — and you are building on sand.

What to expect as a patient

Peripheral nerves repair slowly, on the order of about a millimeter a day at best, so this is a months-long process measured in gradual change, not an overnight fix. A realistic plan begins with evaluation and diagnostics to map which drivers are active, sets expectations honestly, and adjusts over time based on response. Some patients experience meaningful improvement; results vary by individual and by how advanced the nerve loss is at the start. The earlier the terrain is corrected, the more nerve there is to save.

Frequently asked questions

Key takeaways

• Standard drugs mute the pain signal but do not repair the nerve; partial relief and side effects are common.
• The Regenerve protocol treats the terrain first, then calms overfiring nerves, then supports structural and mitochondrial repair.
• The 8% capsaicin patch is FDA-approved for painful diabetic neuropathy of the feet and provides real, if modest, pain relief; nerve-regrowth claims remain under investigation.
• Orthobiologics (PRP, BMAC) and mitochondrial peptides (SS-31) are biologically rational and belong in an individualized plan.
• Nerve repair is slow; earlier intervention preserves more function.

This article is educational and is not a substitute for evaluation, diagnosis, or treatment by a physician. Individual results vary. Do not start, stop, or change any medication or treatment without consulting your physician. Ready to start? Take the free Nerve Damage Score or call/text (314) 886-5902.

References

1. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–820.
2. Simpson DM, Robinson-Papp J, Van J, et al. Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomized, double-blind, placebo-controlled study (STEP). J Pain. 2017;18(1):42–53.
3. U.S. FDA. Qutenza (capsaicin) 8% topical system — approval for neuropathic pain associated with diabetic peripheral neuropathy of the feet. 2020.
4. Vinik AI, et al. Capsaicin 8% patch repeat treatment plus standard of care in painful diabetic peripheral neuropathy: 52-week open-label safety study (PACE). BMC Neurol. 2016;16:251.
5. Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the 8% capsaicin patch. Br J Anaesth. 2011;107(4):490–502.
6. Sánchez M, et al. Platelet-rich plasma and peripheral nerve regeneration (review of preclinical and early clinical evidence).
7. Szeto HH. First-in-class cardiolipin-protective compound (SS-31/elamipretide) as a therapeutic agent for mitochondrial dysfunction. Br J Pharmacol. 2014.

Note: References 6–7 point to real bodies of work but should be matched to specific, current citations at publication.

There is a treatment for neuropathic foot pain that is FDA-approved, non-opioid, non-systemic, and applied in a doctor’s office in under an hour — and yet many patients living with burning feet have never been offered it. It is the high-concentration 8% capsaicin patch. This article explains how it works, what the clinical evidence genuinely shows, why it often takes more than one treatment to see the full benefit, and how it fits into a repair-focused protocol. It also draws a careful line between what is proven and what is still being studied — because that distinction is exactly what “mainstream medicine missed” conversations tend to blur.

A note on numbers, up front

You may have seen a very high success figure attached to this protocol. In the interest of honesty: the controlled clinical trials of the 8% capsaicin patch show modest but statistically significant pain relief, not near-universal cure. Any higher real-world success rate reported by an individual clinic reflects that clinic’s own patient population, protocol, and outcome definition — it is a practice observation, not a figure from the randomized trials, and it should be understood that way. What follows sticks to the published science, then explains where clinical experience extends beyond it.

The receptor that makes chili peppers hot

Capsaicin is the compound that gives chili peppers their heat. It acts on a specific sensor on pain-sensing nerve endings called the TRPV1 receptor (transient receptor potential vanilloid 1). TRPV1 is the same receptor that responds to noxious heat — which is why capsaicin literally feels hot.

Low-dose capsaicin creams (0.025–0.075%) available over the counter provide mild, temporary relief and must be applied several times a day. The prescription 8% patch is a different order of magnitude — roughly a hundredfold more concentrated — and is designed to do something the creams cannot: temporarily defunctionalize the overactive pain fibers.

Defunctionalization: turning down an alarm that won’t stop

In chronic neuropathy, the small C-fibers in the skin become pathologically hyperexcitable. They fire pain signals continuously, even without a real stimulus — the alarm is stuck on. A single, controlled 30-minute application of the 8% patch delivers enough capsaicin to overstimulate those TRPV1-bearing endings and then reversibly quiet them. The nerve endings retract and stop transmitting their runaway pain signals; over the following weeks and months they gradually recover. Crucially, controlled studies found this happens without degrading normal sensation — patients retained their ability to feel sharp, warm, cold, and vibration stimuli.

Because the treatment is topical and non-systemic, it sidesteps the sedation, dizziness, and cognitive fog that limit oral neuropathic-pain drugs. The main side effect is temporary burning and redness at the application site, which is why the patch is applied in a clinical setting, often with skin pre-treatment for comfort.

What the evidence shows

The 8% patch first earned FDA approval in 2009 for postherpetic neuralgia (the lingering nerve pain after shingles). In 2020, on the strength of the pivotal STEP trial led by Dr. David Simpson, the FDA extended approval to painful diabetic peripheral neuropathy of the feet. In STEP, a single 30-minute treatment produced a statistically significant reduction in average daily pain compared with placebo. A separate 52-week study (PACE) confirmed that repeated treatments were well tolerated over a full year, with no worsening of sensory function.

This is the honest headline: the patch reliably and safely reduces pain for a meaningful share of patients, and it can be repeated approximately every three months.

Why persistence matters

One reason patients — and sometimes physicians — give up too soon is that they expect a single patch to do everything. The data and clinical experience both suggest the benefit often builds across successive cycles. Each treatment quiets the overfiring fibers again and extends the window of reduced pain. For a chronic condition that took years to develop, expecting resolution from one application is unrealistic; the protocol is designed around repeated, spaced treatments.

Can it help nerves regrow?

Here is where the science is genuinely exciting but not yet settled. Because capsaicin causes nerve endings to retract and then regenerate, researchers have asked whether repeated treatment might not just relieve pain but actually encourage healthier re-innervation of the skin — in other words, whether it could be disease-modifying. A randomized trial in the United Kingdom is formally testing exactly this question in diabetic neuropathy.

Until that kind of study reports, the responsible position is: the 8% patch is proven for pain relief, and its potential to modify the underlying nerve damage is a promising hypothesis under active investigation. Regenerve’s approach uses the pain-relief window the patch creates as the foundation for the repair-focused steps — orthobiologics and mitochondrial and metabolic support — that aim at the nerve itself. Those regenerative components, as covered in the protocol article, are themselves emerging and individualized rather than guaranteed.

Who is a candidate

The patch is used for localized neuropathic pain, classically in the feet for diabetic neuropathy and in the affected area for postherpetic neuralgia. Suitability depends on a physician’s evaluation of the pain distribution, skin integrity, and overall picture. As with any treatment, it works best as part of a plan that also addresses the root drivers of the neuropathy rather than as a standalone fix.

Frequently asked questions

Key takeaways

• The 8% capsaicin patch is FDA-approved for painful diabetic neuropathy of the feet (2020) and postherpetic neuralgia (2009).
• It works by reversibly quieting overfiring TRPV1 pain fibers, without degrading normal sensation, and without systemic side effects.
• Trial evidence supports real but modest pain relief; benefit often builds across repeated treatments.
• Whether it can help nerves regenerate is a legitimate, still-unproven hypothesis under study.
• It works best inside a plan that also treats the neuropathy’s root causes.

This article is educational and is not a substitute for evaluation, diagnosis, or treatment by a physician. Individual results vary. Do not start, stop, or change any treatment without consulting your physician. Take the free Nerve Damage Score or call/text (314) 886-5902.

References

1. Simpson DM, Robinson-Papp J, Van J, et al. Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomized, double-blind, placebo-controlled study (STEP). J Pain. 2017;18(1):42–53.
2. U.S. FDA. Qutenza (capsaicin) 8% topical system — approval for painful diabetic peripheral neuropathy of the feet. 2020; original PHN approval 2009.
3. Vinik AI, et al. Capsaicin 8% patch repeat treatment plus standard of care in painful diabetic peripheral neuropathy: 52-week open-label safety study (PACE). BMC Neurol. 2016;16:251.
4. Anand P, Bley K. Topical capsaicin for pain management: mechanisms of action of the 8% capsaicin patch. Br J Anaesth. 2011;107(4):490–502.
5. Abrams RMC, et al. A critical review of the capsaicin 8% patch for diabetic peripheral neuropathy of the feet. Expert Rev Neurother. 2021.